Revelation Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Revelation Biosciences, Inc. carries a market capitalization of 2.13M, placing it among publicly traded companies globally. Its enterprise value stands at -6.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.13M |
| Enterprise Value | -6.72M |
Share Statistics
Revelation Biosciences, Inc. currently has 3.91M shares outstanding.
| Shares Outstanding | 3.91M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | -0.26 |
| P/OCF Ratio | -0.25 |
Financial Position
Revelation Biosciences, Inc. maintains a current ratio of 6.21, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.21 |
| Quick Ratio | 6.11 |
| Debt / Equity | 7.35 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -154.77 |
| Return on Assets (ROA) | -120.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Revelation Biosciences, Inc.'s stock has declined approximately -89.37075% over the past 52 weeks. The 50-day moving average sits at 6.48, while the 200-day moving average is 8.62.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.37075% |
| 50-Day Moving Average | 6.48 |
| 200-Day Moving Average | 8.62 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.24M, while operating income came in at -11.27M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.27M |
| Pretax Income | -10.75M |
| Net Income | -10.75M |
| EBITDA | -11.24M |
| EBIT | -11.27M |
| Earnings Per Share (EPS) | -4.66 |
Balance Sheet
Revelation Biosciences, Inc. holds 11.48M in cash and equivalents against 739,916.00 in total debt, resulting in a net debt position of -11.48M. Total book value stands at 10.07M, with working capital of 9.80M providing operational flexibility.
| Cash & Cash Equivalents | 11.48M |
| Total Debt | 739,916.00 |
| Net Debt | -11.48M |
| Equity (Book Value) | 10.07M |
| Book Value Per Share | 2.58 |
| Working Capital | 9.80M |
Cash Flow
Revelation Biosciences, Inc. produced -9.33M in operating cash flow over the past twelve months. After subtracting -111,507.00 in capital expenditures, free cash flow totaled -9.44M - equivalent to -4.09 per share.
| Operating Cash Flow | -9.33M |
| Capital Expenditures | -111,507.00 |
| Free Cash Flow | -9.44M |
| FCF Per Share | -4.09 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -391.20 |
| FCF Yield | -388.10 |
Stock Splits
Revelation Biosciences, Inc.'s most recent stock split took place on October 20, 2026 with a 7:1 split ratio.
| Last Split Date | 10/20/2026 |
| Split Ratio | 7:1 |
Scores
Revelation Biosciences, Inc. posts an Altman Z-Score of -7.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.29 |